While investment in NASH has waned in the context of rigid histological endpoints and clinical setbacks, opportunities to target obesity and other metabolic disorders through the lens of a holistic approach to metabolic syndrome are exploding.
Saturated with the latest advances in validating non-invasive biomarkers, exploring combination therapy, and novel strategies to leverage GLP-1 receptor agonists, the 6th Obesity & NASH Drug Development Summit (previously the NASH Summit) is dedicated to reuniting industry leaders in person to share cross-industry insight. Taking place from November 29 – December 1 in Boston, this is a conversation you won’t want to miss.
Access the full event guide to see the complete agenda and expert speakers confirmed to present.
Unmissable Highlights Include:
- Interrogate the latest advances in combination therapy, developing oral therapies, and innovative trial design for the treatment of obesity with Novo Nordisk, Eli Lilly, and Pfizer to accelerate clinical success in drug-based management of obesity
- Redefine the clinical pathway through assessing implementation and validation of non-invasive biomarkers and digital pathology with AstraZeneca, the FDA, and Pfizer to drive a more standardized and accurate understanding of efficacy and evolve endpoints
- Navigate exciting therapeutic targets, alternative patient inclusion criteria in clinical trials, and regenerative medicine with Boehringer Ingelheim, Bayer, and Inventiva to consolidate promising targets and reimagine clinical development
Take a look at the complete program here.
As Eli Lilly scores in weight loss with Tirzepatide and Madrigal and Intercept fight for clinical success in the next wave of NASH therapeutics, industry professionals are debating what’s next. Attending this summit is your opportunity to share your perspectives and forge the next steps in bringing meaningful therapies to patients.
Early bird & team discounts are available – Secure your place today.
This post was originally published on Source Link